KIT and asthma: For example, barzolvolimab, a monoclonal antibody against KIT, has been shown to be effective in chronic prurigo and chronic urticaria [42], and imatinib, a KIT inhibitor, can reduce airway hyperresponsiveness in patients with severe asthma through mast cell depletion [43].